Citius Pharmaceuticals, Inc. (CTXR) Stock Price & Analysis
Citius Pharmaceuticals, Inc. (CTXR) fell 2.07% to USD 0.52 as of July 25, 2026 at 15:02 UTC, according to Nexqual real-time market data.
CTXR last closed at USD 0.53; the session ranged USD 0.5–0.54 on volume of 176,619 shares. Market capitalization is $14.28M, with a 52-week range of USD 0.47–2.19 (NCM). Source: Nexqual, July 25, 2026 at 15:02 UTC.
Key Statistics (as of July 25, 2026 at 15:02 UTC)
| Price | USD 0.52 |
|---|---|
| Change | ▼ 2.07% (down) |
| Previous Close | USD 0.53 |
| Open | USD 0.52 |
| Day Range | USD 0.5 – 0.54 |
| 52-Week Range | USD 0.47 – 2.19 |
| Volume | 176,619 shares |
| Market Cap | $14.28M |
| Exchange | NCM |
Technical Analysis (CTXR)
Nexqual's technical model rates CTXR "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 15:02 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.03 (neutral) |
| vs SMA50 | Below (USD 0.58) |
| MACD | -0.02 (negative) |
Analyst Ratings (CTXR)
Wall Street analysts rate CTXR "None" based on 1 analysts, with a mean price target of USD 4 (range USD 4–4), per Nexqual as of July 25, 2026 at 15:02 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 4 |
| High Target | USD 4 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CTXR)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.36 |
| Revenue Estimate | $5.46M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.38 vs est -0.3 ▼ miss |
| 2025-09-30 | USD -0.11 vs est -0.24 ▲ beat |
| 2025-06-30 | USD -0.8 vs est -0.21 ▼ miss |
Source: Nexqual, July 25, 2026 at 15:02 UTC.
Financials & Fundamentals (CTXR)
| Total Revenue | $5.61M |
|---|---|
| Gross Margin | +80.07% |
| Operating Margin | -1827.78% |
| Profit Margin | +0.00% |
| ROE | -83.60% |
| Debt / Equity | 1.17 |
| Current Ratio | 0.58 |
| Total Cash | $4.59M |
| Total Debt | $808,162 |
| Free Cash Flow | $-33.46M |
Source: Nexqual, July 25, 2026 at 15:02 UTC.
Financial Health Score (CTXR)
Nexqual rates Citius Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:02 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $5M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$32M |
| Efficiency | Critical — ROE -84%, ROA -27.6% |
Ownership (CTXR)
| Insider Ownership | +1.80% |
|---|---|
| Institutional Ownership | +3.73% |
| Shares Outstanding | 27.45M |
| Float | 26.96M |
| Short % of Float | +18.48% |
Source: Nexqual, July 25, 2026 at 15:02 UTC.
Leadership (CTXR)
Citius Pharmaceuticals, Inc. is led by Leonard L. Mazur (age 80), Co-Founder, CEO, Chairman & Secretary, per Nexqual as of July 25, 2026 at 15:02 UTC.
| Co-Founder, CEO, Chairman & Secretary | Leonard L. Mazur (age 80) |
|---|---|
| Co-Founder & Executive Vice Chairman | Myron Z. Holubiak (age 78) |
| Chief Business Officer & CFO | Jaime Bartushak (age 57) |
| Executive Vice President of Operations | Gary F. Talarico (age 70) |
| Vice President of Investor Relations & Corporate Communications | Ilanit Allen |
Major Backers & Investors (CTXR)
Notable institutional backers of Citius Pharmaceuticals, Inc. include Fidelity, HRT Financial LP, Asset Advisory Group, Inc., according to Nexqual as of July 25, 2026 at 15:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.68% |
| HRT Financial LP | 0.22% |
| Asset Advisory Group, Inc. | 0.21% |
| UBS Group AG | 0.2% |
| Susquehanna International Group, LLP | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.5% |
| Geode Capital | 0.9% |
| BlackRock | 0.25% |
| Northern Trust | 0.16% |
Source: Nexqual, July 25, 2026 at 15:02 UTC.
From Citius Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-12-23)
Key Strengths & Strategy (as disclosed to the SEC)
- As the FDA considered this a new product, an Investigational New Drug Application ("IND") was filed.
- Moreover, no new safety signals were identified.    In December 2022, a Biologics License Application ("BLA") for LYMPHIR was accepted for filing with the FDA and a PDUFA goal date was set for July 28, 2023.   In July 2023, the FDA issued a complete response letter ("CRL") requiring us to incorporate enhanced product testing and additional controls agreed to with the FDA during the market application review.
- The FDA provided clear, constructive, and actionable guidance during the discussion, underscoring a pathway to support a future New Drug Application (NDA) submission for Mino-Lok.
- Citius Pharma will continue to have ongoing engagement with the FDA regarding the next steps of development.    17   Market Opportunity   The current market for OTC and topical prescription ("Rx") products for the symptomatic treatment of hemorrhoids is highly fragmented and includes approximately 20 million units of OTC and over 4 million prescriptions.
Partnerships
- SpinCo began operations in April 2022, when Citius Pharma transferred the assets related to LYMPHIR to SpinCo, including the related license agreement with Eisai Co., Ltd. ("Eisai") and the related asset purchase agreement with Dr.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATOS | Atossa Therapeutics, Inc. | USD 2.3 | ▼ 5.56% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 9.88 | ▼ 6.7% |
| GNPX | Genprex, Inc. | USD 7.81 | ▼ 7.13% |
| SENS | Senseonics Holdings, Inc. | USD 4.86 | ▲ 0% |
| DARE | Dare Bioscience, Inc. | USD 1.28 | ▲ 4.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:02 UTC. This page is informational and not investment advice.